Long GV, et al. - Nivolumab monotherapy and combination nivolumab plus ipilimumab have been shown to increase proportions of patients achieving a response and survival vs ipilimumab in patients with metastatic melanoma. In the treatment of active melanoma brain metastases, efficacy as well as safety of nivolumab alone or in combination with ipilimumab was assessed. Both treatment options were active in melanoma brain metastases. Nivolumab combined with ipilimumab allowed a high proportion of patients to achieve an intracranial response and therefore, was recommended to be considered as a first-line therapy for patients with asymptomatic untreated brain metastases.